Current state of evidence of cannabis utilization for treatment of autism spectrum disorders Rumi Agarwal, Shanna L. Burke and Marlaina Maddux BMC Psychiatry, 2019, 19, 328 Doi : 10.1186/s12888-019-2259-4 Abstract The core symptoms and co-morbidities associated with autism spectrum disorders (ASD) affect daily living and quality of life. Existing pharmacological interventions are only able to attenuate some related symptoms but are unable to address the underlying etiologies associated with ASD. Anecdotal evidence, which claims benefit from the use of cannabis to treat symptoms among this population, has been gaining popularity as families seek solutions. This paper analyzed recent peer-reviewed literature to identify the current state of [...]
Lire la suiteThe effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD) Charlotte M. Pretzsch, Bogdan Voinescu, Maria A. Mendez, Robert Wichers, Laura Ajram, Glynis Ivin, Martin Heasman, Steven Williams, Declan GM Murphy, Eileen Daly and Gráinne M. McAlonan Journal of Psychopharmacology, 2019, Vol. 33, (9), 1141–1148 Doi : 10.1177/0269881119858306 Abstract Background : The potential benefits of cannabis and its major non-intoxicating component cannabidiol (CBD) are attracting attention, including as a potential treatment in neurodevelopmental disorders such as autism spectrum disorder (ASD). However, the neural action of CBD, and its relevance to ASD, remains [...]
Lire la suiteEffects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms : An Observational Study of 18 Participants Undergoing Compassionate Use Paulo Fleury-Teixeira, Fabio Viegas Caixeta, Leandro Cruz Ramires da Silva, Joaquim Pereira Brasil-Neto and Renato Malcher-Lopes Frontiers in Neurology, 2019, volume 10, Article 1146, 1-9. doi : 10.3389/fneur.2019.01145 Autism Spectrum Disorders comprise conditions that may affect cognitive development, motor skills, social interaction, communication, and behavior. This set of functional deficits often results in lack of independence for the diagnosed individuals, and severe distress for patients, families, and caregivers. There is a mounting body of evidence indicating the effectiveness of pure cannabidiol (CBD) and [...]
Lire la suiteOral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities Dana Barchel, Orit Stolar2, Tal De-Haan, Tomer Ziv-Baran, Naama Saban, Danny Or Fuchs, Gideon Koren and Matitiahu Berkovitch Frontiers in Pharmacology, 2019, volume 9, article 1521, 1-5 Doi : 10.3389/fphar.2018.01521 Objective : Children with autism spectrum disorder (ASD) commonly exhibit comorbid symptoms such as aggression, hyperactivity and anxiety. Several studies are being conducted worldwide on cannabidiol use in ASD; however, these studies are still ongoing, and data on the effects of its use is very limited. In this study we aimed to report the experience of parents who administer, [...]
Lire la suiteOpioid and healthcare service use in medical cannabis patients with chronic pain: a prospective study Sharon Sznitman, Carolyn Mabouk, Zahi Said and Simon Vulfsons British Medical Journal, 2021. doi : 10.1136/bmjspcare-2020-002661 Abstract Background Various jurisdictions have legalised medical cannabis (MC) for use in chronic pain treatment. The objective of this study was to determine if the use of MC is related to a reduction in the use of prescription opioids and other prescription medications and healthcare services. Methods : A retrospective cohort study was conducted using the medical files of 68 Israeli patients with chronic pain using MC. Number of prescription medications filled and healthcare services [...]
Lire la suiteA Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate Potential Drug-Drug Interactions Between Cannabidiol and Clobazam Kevan E. Van Landingham, MD, PhD1, Julie Crockett, PhD2, Lesley Taylor, PhD2*, and Gilmour Morrison, HND2 The Journal of Clinical Pharmacology, 2020, 0, (0), 1–10 Doi : 10.1002/jcph.1634 Abstract We investigated the effects of cannabidiol (CBD; 21-day maintenance dose) on the pharmacokinetics (PK) of clobazam (CLB) and monitored the safety of CBD (or placebo) plus CLB in 20 patients with uncontrolled epilepsy on stable doses of CLB. Blood samples collected until 24 hours postdose were evaluated by liquid chromatography tandem mass spectrometry. PK parameters of CLB and major metabolite N-desmethylclobazam (N-CLB), [...]
Lire la suiteShort and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder Emily M. LaFrance, Nicholas C. Glodosky, Marcel Bonn-Miller, Carrie Cuttler Journal of Affective Disorders, 2020, 274, 298–304 Doi : 10.1016/j.jad.2020.05.132 A B S T R A C T Background : Many individuals use cannabis to manage symptoms of post-traumatic stress disorder (PTSD), and evidence indicates that the endocannabinoid system represents a viable target for treating these symptoms. Method : Data from 404 medical cannabis users who self-identified as having PTSD were obtained from Strainprint®, a medical cannabis app that patients use to track changes in symptoms as a function of different strains and doses [...]
Lire la suiteStudy finds no evidence marijuana use increases stroke risk HealthDay News, 2020. https://www.upi.com/Health_News/2020/06/04/Study-finds-no-evidence-marijuana-use-increases-stroke-risk/3321591274273/?upi_ss=Cannabis An observational study conducted at hospitals found no evidence that marijuana use increases risk for stroke. File Photo by Atomazul/Shutterstock Whether pot use increases the risk of stroke has been hotly debated, and now a new study adds to evidence that it doesn't. "Our observational study looked specifically at recent cannabis use by reviewing drug testing data for people admitted to the hospital. While more research is needed with larger numbers of people, our study lends support to the studies showing that cannabis use does not increase the risk of stroke," said [...]
Lire la suiteEfficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health CareWorkers During the COVID-19 Pandemic. A Randomized Clinical Trial José Alexandre S. Crippa, PhD; AntonioW. Zuardi, PhD; Francisco S. Guimarães, PhD; Alline Cristina Campos, PhD; Flávia de Lima Osório, PhD; Sonia Regina Loureiro, PhD; Rafael G. dos Santos, PhD; José Diogo S. Souza, MD; Juliana Mayumi Ushirohira, MD, MSc; Julia Cozar Pacheco, RPh; Rafael Rinaldi Ferreira, PhD, RPh; Karla Cristinne Mancini Costa, MSc; Davi Silveira Scomparin, MSc; Franciele Franco Scarante, MSc; Isabela Pires-Dos-Santos, VMD; Raphael Mechoulam, PhD; Flávio Kapczinski, PhD; Benedito [...]
Lire la suiteProtective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions Nicole L. Stone, Timothy J. England, and Saoirse E. O’Sullivan Cannabis and Cannabinoid Research, 2021, Doi : 10.1089/can.2020.0159 Abstract Background and Objectives : Preclinical studies have shown cannabidiol is protective in models of ischemic stroke. Based on results from our recent systematic review, we investigated the effects of two promising neuroprotective phytocannabinoids, cannabigerol (CBG) and cannabidivarin (CBDV), on cells of the blood–brain barrier (BBB), namely human brain microvascular endothelial cells (HBMECs), pericytes, and astrocytes. Experimental Approach : Cultures were subjected to oxygen-glucose deprivation (OGD) protocol to model ischemic stroke and cell [...]
Lire la suite